In the wake of mounting evidence for the efficacy of psychedelic-assisted therapies, the U.S. Food and Drug Administration (FDA) is considering approving psilocybin, the active ingredient in 'magic mushrooms,' for treating depression in the near future.
Genomic PressSep 13 2024 In the wake of mounting evidence for the efficacy of psychedelic-assisted therapies, the U.S. Food and Drug Administration is considering approving psilocybin, the active ingredient in "magic mushrooms," for treating depression in the near future.
Our findings suggest that if the FDA gives the green light, psilocybin-assisted therapy has the potential to help millions of Americans who suffer from depression. This underscores the importance of understanding the practical realities of rolling out this novel treatment on a large scale." To arrive at their projections, the researchers first determined that of the nearly 15 million American adults with depression, about 9 million receive treatment in a given year.
Related StoriesThe researchers caution that these projections are highly contingent on the precise FDA approval parameters and subsequent real-world implementation factors. Insurance coverage decisions, availability of trained practitioners, and regional variations in access could all considerably constrain the ultimate uptake of psilocybin therapy. Additionally, if approval encompasses off-label use for conditions beyond depression, demand could further surge in unpredictable ways.
Depression Efficacy Food Genomic Medicine Research
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
US policymakers should embrace MDMAThe Food and Drug Administration’s rejection of MDMA-assisted therapy is a missed opportunity
Read more »
This week could bring FDA approval of fall COVID-19 vaccinesUpdated COVID-19 vaccines may receive approval from the U.S. Food and Drug Administration this week.
Read more »
Cancer drug could treat early-stage Alzheimer's disease, study showsA type of drug developed for treating cancer holds promise as a new treatment for neurodegenerative diseases such as Alzheimer's, according to a study by researchers at Penn State, Stanford University and an international team of collaborators.
Read more »
Study reveals significant increase in drug overdoses in Colombia among young womenOverdose rates in Colombia involving illegal opioids, hallucinogens, stimulants and sedative psychotropic medication increased greatly during 2018-2021, mainly caused by overdoses in young women, according to a study at Columbia University Mailman School of Public Health.
Read more »
Common diabetes drug slows growth of normal cells carrying cancer mutation, finds studyA common diabetes medication, metformin, slows the growth of precancerous cells in the esophagus while some metabolic conditions accelerate it, suggests a new study.
Read more »
Mouse study reveals new central action target of weight loss drug GLP-1R agonistsA research group led by Prof. Zhu Yingjie from the Shenzhen Institute of Advanced Technology (SIAT) of the Chinese Academy of Sciences has revealed the essential role of lateral septum (LS) neurons in mediating anorectic and weight-lowering effects of the anti-obesity drug, liraglutide, in mice.
Read more »